Publications

Detailed Information

p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: Quantitation using pyrosequencing study

DC Field Value Language
dc.contributor.authorYoon, Jong Hyun-
dc.contributor.authorLee, Dong Soon-
dc.contributor.authorKim, Miyoung-
dc.contributor.authorKim, Song-yee-
dc.contributor.authorKim, Young Tae-
dc.contributor.authorHwang, Sang Mee-
dc.contributor.authorPark, Hyun-Kyung-
dc.contributor.authorOh, Bora-
dc.contributor.authorShe, Cha Ja-
dc.contributor.authorYoon, Sung Soo-
dc.contributor.authorYang, Inchul-
dc.date.accessioned2012-05-23T01:39:50Z-
dc.date.available2012-05-23T01:39:50Z-
dc.date.issued2010-06-
dc.identifier.citationLEUKEMIA RESEARCH; Vol.34 6; 718-722ko_KR
dc.identifier.issn0145-2126-
dc.identifier.urihttps://hdl.handle.net/10371/76297-
dc.description.abstractWe investigated how the quantity of p15INK4b methylation related to International Prognosic Scoring System variables and survival in 74 patients with de novo myelodysplastic syndrome (MDS). Pyrosequencing of 11 consecutive CpG sites of the p15INK4b promotor region was performed, with the extent of CpG cytosine methylation assessed in terms of methylation level (MtL). Patients with >5% bone marrow blasts had higher MtL than patients with <5% blasts (10.1% vs. 6.1%, p = 0.030, respectively). Methylation was not associated with chromosomal aberrations. The MtL of patients with thrombocytopenia were higher than patients without thrombocytopenia (11.2% vs. 6.2%, p = 0.036, respectively); they were higher in patients with cytopenias in >= 2 lineages than in patients with either unilineage or no cytopenia (9.8% vs. 4.1%, p = 0.036, respectively). The survival of patients with >7% MtL was worse than patients with <7% MtL (p = 0.031). Heavy p15INK4b methylation in MDS is associated with IPSS predictors of poor prognosis and adverse survival. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDko_KR
dc.subjectp15INK4bko_KR
dc.subjectPrognosisko_KR
dc.subjectMyelodysplastic syndromesko_KR
dc.subjectMethylationko_KR
dc.subjectPyrosequencingko_KR
dc.titlep15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: Quantitation using pyrosequencing studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김미영-
dc.contributor.AlternativeAuthor오보라-
dc.contributor.AlternativeAuthor김송이-
dc.contributor.AlternativeAuthor박현경-
dc.contributor.AlternativeAuthor황상미-
dc.contributor.AlternativeAuthor김영태-
dc.contributor.AlternativeAuthor양인철-
dc.contributor.AlternativeAuthor윤성수-
dc.contributor.AlternativeAuthor윤종현-
dc.contributor.AlternativeAuthor이동순-
dc.identifier.doi10.1016/j.leukres.2009.09.007-
dc.citation.journaltitleLEUKEMIA RESEARCH-
dc.description.citedreferenceGao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170-
dc.description.citedreferenceNimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139-
dc.description.citedreferenceLee ES, 2008, CLIN CANCER RES, V14, P2664, DOI 10.1158/1078-0432.CCR-07-1232-
dc.description.citedreferenceYang R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-124-
dc.description.citedreferenceMUFTI GJ, 2008, CANC CONTROL, V15, pS14-
dc.description.citedreferenceTost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314-
dc.description.citedreferenceBrakensiek K, 2007, CLIN CHEM, V53, P17, DOI 10.1373/clinchem.2007.072629-
dc.description.citedreferenceMcDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal/pbio.0040051-
dc.description.citedreferenceShaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972-
dc.description.citedreferenceHerman JG, 1996, P NATL ACAD SCI USA, V93, P9821-
dc.description.citedreferenceUchida T, 1997, BLOOD, V90, P1403-
dc.description.citedreferenceQuesnel B, 1998, BLOOD, V91, P2985-
dc.description.citedreferenceRonaghi M, 1998, SCIENCE, V281, P363-
dc.description.citedreferenceCameron EE, 1999, BLOOD, V94, P2445-
dc.description.citedreferenceCZEPULKOWSKI B, 2001, HUMAN CYTOGENETICS M, P1-
dc.description.citedreferenceTien HF, 2001, BRIT J HAEMATOL, V112, P148-
dc.description.citedreferenceUhlmann K, 2002, ELECTROPHORESIS, V23, P4072-
dc.description.citedreferenceAu WY, 2003, BRIT J HAEMATOL, V120, P1062-
dc.description.citedreferenceTHIELE J, 1991, J CLIN PATHOL, V44, P300-
dc.description.citedreferenceColella S, 2003, BIOTECHNIQUES, V35, P146-
dc.description.citedreferenceChim CS, 2003, ANN HEMATOL, V82, P738, DOI 10.1007/s00277-003-0744-8-
dc.description.citedreferenceSHAFFER LG, 2005, ISCN 2005 INT SYSTEM-
dc.description.citedreferenceMARSH S, 2005, METH MOL B, V311, P97-
dc.description.citedreferenceDupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007-
dc.description.citedreferenceCottrell SE, 2004, CLIN BIOCHEM, V37, P595, DOI 10.1016/j.clinbiochem.2004.05.010-
dc.description.citedreferenceLIST AF, 2004, AM SOC HEMATOL ED PR, P297-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share